MedTrace Logo

Panzyga in CIDP Administered at Different Infusion Rates

NCT03166527 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-05-25

No results posted yet for this study

Summary

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune globulin), which is infused in a set regimen that requires 4-5 hours in a hospital day unit, taking up resources such as nursing time and hospital space. Chronic treatment is required in most cases.

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Interventions

DRUG

Immune Globulin 10% Intravenous Solution

standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.

Sponsors & Collaborators

  • Vera Bril

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2018-12-15
Completion
2018-12-15

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03166527 on ClinicalTrials.gov